Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting - Retrospective Drug Use Proposals

FRIDAY, JULY 23, 2021

HTTP://WWW.TXVENDORDRUG.COM/
Revised Criteria

1. Acetylcholinesterase Inhibitors
2. Cyclooxygenase-2 Inhibitors
3. Histamine H2-Receptor Antagonists
4. Ketorolac (Oral)
5. Leukotriene Receptor Antagonists
6. Mecasermin
7. Memantine
Revised criteria: Acetylcholinesterase Inhibitors

Criteria set reviewed:
• No updates required

References:
• Reviewed & updated
Revised criteria: Cyclooxygenase-2 Inhibitors

**Dosage:**
- Updated sentence to reflect that Consensi® (celecoxib/ amlodipine) is now on the market

**References:**
- Reviewed & updated
Revised criteria: Histamine H2-Receptor Antagonists

Dosage:
- Added information about removal of ranitidine from the market
- Added statement that Zantac® is trade name for ranitidine, but they are remarketing under the name Zantac 360® (famotidine)
- Table 1:
  - Added dosage information for Zantac 360® (famotidine)
  - Removed ranitidine dosage information
- Added statement about the combination product Duexis® (famotidine/ibuprofen)
- Created Table 3. Adult Maximum Dose for Histamine H2-Receptor Antagonists: Combination Therapy
Revised criteria: Histamine H2-Receptor Antagonists

**Dosage:**
- Table 4
  - Added Zantac 360°® (famotidine)
  - Removed ranitidine
- Table 5
  - Removed ranitidine
- Table 6
  - Removed ranitidine

**References:**
- Reviewed & updated
Revised criteria: Ketorolac (Oral)

Criteria set reviewed:
• No updates required

References:
• Reviewed & updated
Revised criteria: Ketorolac (Oral)

Criteria set reviewed:
• No updates required

References:
• Reviewed & updated
Revised criteria: Leukotriene Receptor Antagonists

Criteria set reviewed:
• No updates required

References:
• Reviewed & updated
Revised criteria: Mecasermin

Criteria set reviewed:
• No updates required

References:
• Reviewed & updated
Revised criteria: Memantine

Dosage:
• Updated wording to reflect that Namzaric® (donepezil/memantine) is no longer a new product

References:
• Reviewed & updated
Texas Medicaid Vendor Drug Program Drug Utilization Review Board Meeting - Retrospective Drug Use Proposals

FRIDAY, JULY 23, 2021

HTTP://WWW.TXVENDORDRUG.COM/